Brian Goldstein, co-chair of Choate's Business & Technology Group, and a former member of the Firm Committee, has over 25 years of experience in the areas of general business, venture capital, technology and life sciences transactions, and M&A.
Mr. Goldstein previously served as Assistant General Counsel at Groundwater Technology, Inc., where he handled SEC reporting; acquisitions, divestitures, and joint ventures; and the sale of a controlling interest of the company to Fluor Daniel.
He is listed in The Legal 500, Best Lawyers in America and is named a Massachusetts Super Lawyer.
Business & Technology: counsel to innovative companies and leading investors in biotech, medical devices, HealthIT and healthcare services, advising on financings, strategic partnerships and licensing agreements, merger and acquisitions, and general business counseling. His international practice includes cross-border financings and acquisitions, as well as advice on other U.S.-based activities, for companies headquartered or with significant operations in Israel.
Mergers & Acquisitions: national and cross-border mergers and acquisitions on behalf of public and private companies in a wide range of industries.
Private Equity: recapitalizations and investments in early stage ventures and later stage companies for private equity and venture capital firms.
Venture Capital & Private Equity Matters
- Representation of Leerink Transformation Partners in growth equity investments in Health IT and Healthcare Services companies.
- Representation of Broadview Ventures in investments in early stage cardiovascular medical device and therapeutic companies.
- Representation of MP Healthcare Venture Management, a member of the Mitsubishi Tanabe Pharma Group, in investments in early-stage biotech companies.
- Representation of Chondrial Therapeutics in equity investment by Deerfield Management.
- Representation of Lantos Technologies in equity investments by RA Capital and Catalyst Health Ventures.
- Representation of Cyteir Therapeutics in equity financing by Venrock Partners, Celgene, Lightstone Ventures and DROIA Oncology Ventures.
- Representation of Vero Biotech in equity and debt investments by Brace Pharma Capital.
- Representation of AppCard in equity investments by Founders Fund, Innovation Endeavors, Jerry Yang, and PLDT Capital.
- Representation of Quobyte in equity investments by Samsung Electronics and Target Partners.
Mergers & Acquisitions Matters
- Representation of Cosman Medical in sale to Boston Scientific.
- Representation of Bournewood Health Systems to Alita Care, a portfolio company of Kholberg & Company.
- Representation of Shire in strategic investment and “Build to Buy” transactions with Nimbus Discovery, Inception 1, and ArmaGen.
- Representation of Answers Corp. in sale of its Webcollage Division to Gladson, a portfolio company of The Wicks Group.
- Representation of Yodle, Inc. in acquisitions of Lighthouse Practice Management, ProfitFuel, and CyberCare.
- Representation of AppCard in acquisition of ProLogic Retail Services.
- Representation of Carbon Design Systems in sale to ARM Ltd.
- Representation of Dotomi, Inc. in merger with ValueClick.
- Representation of Retail Convergence, Inc. (parent company of Rue La La and SmartBargains e-commerce sites) in merger with GSI Commerce.
Licensing & Strategic Partnerships Matters
- Representation of molecular therapeutics company in “Build to Buy” transaction with Abbvie.
- Representation of tissue engineering company in R&D collaboration agreement with Fortune 50 consumer products company.
- Representation of Israeli-based company in license transaction with Fortune 500 media and cable company.
Publications and Presentations
- “The Evolution of Finance,” panelist, Boston Biotech Forum, September 2018.
- “Starting a Biotech Company: Where to Begin,” webinar presenter, Xconomy, March 2018.
- On-going presenter at UMass Lowell Innovation Hub Education Series for Technology Start-ups.
- “Driving Innovation & Success,” panelist, Massachusetts Advanced Manufacturing Summit, September 2016.
- “Option Deals for Biotech: Ensuring They are Enforceable,” author, Mergers & Acquisitions Law360, December 2014.
- “Women’s Enterprise Initiative Business Forum,” panelist, Women’s Enterprise Initiative, September 2014.
- “Crisis Management and Tough Judgment Calls in Representing Emerging Growth Companies,” speaker, Practising Law Institute’s Venture Capital 2014: Nuts and Bolts Program, New York, February 2014, April 2015.
- “Funding Gap for Life Science Companies Is Still a Problem,” co-author, Life Sciences Law360, September 2013.
- “Raising Capital for Start-up Businesses,” panelist, Harvard Business School Association of Boston, February 2013.
Professional and Community Involvement
Mr. Goldstein is a former member of the firm’s Executive Committee and is a member of the American Bar Association, Boston Bar Association, and Association for Corporate Growth.
He currently serves on the board of One Can Help, an organization that helps at-risk children and families involved in the juvenile court system by providing critical resources they urgently need to create positive change in their lives.
Education & Credentials
- University of Virginia School of Law
- JD, 1988
- University of Virginia
- BA, 1983, with honors
Brian 's Insights
Choate will sponsor the BioEntrepreneur Bootcamp & Pitch Contest presented by MassBio & SR One on Tuesday, November 27, 2018.
Brian Goldstein, co-chair of Choate’s Business & Technology Group, will speak on the panel “The Evolution of Finance” at the Boston Biotech Forum on Monday, September 17.
Choate announced today that 48 of its attorneys – more than 75 percent of the Firm’s equity partners – have been selected for inclusion in The Best Lawyers in America© 2019.
Choate recently represented Symbiotix Biotherapies, Inc., a pioneering venture-backed biotechnology company developing novel molecular therapeutics derived from the human microbiome, in negotiating its exclusive license agreement with Harvard University.
Choate recently advised Cyteir Therapeutics in its $29 million Series B preferred stock financing. The investment was led by Venrock, who was joined by returning investors including Celgene, along with new investors Lightstone Ventures and DROIA Oncology Ventures.